Search Results
Jun 08, 2026, 08:30 ET Kye Pharmaceuticals Announces the Availability of Dyanavel® XR Tablets Across Canada for the Treatment of ADHD
emphasize the importance of expanding treatment options that align with patients' diverse needs across different life stages.Dr. Jane Liddle, MD, FRCPC, Paediatrician at Capital Kidz Medical Centre in Ottawa and Chairperson of CADDRA, noted that having additional evidence-based options is meaningful
More news about: Kye Pharmaceuticals Inc.
Jun 08, 2026, 08:04 ET TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Board, TransCode TherapeuticsDan Vlock, MD — Consulting Oncology Clinician, TransCode TherapeuticsZdravka Medarova, PhD — Co-Founder and Chief Scientific Officer, TransCode TherapeuticsLouis Brenner, MD — Consulting Strategic Advisor, TransCode TherapeuticsMichel
More news about: TransCode Therapeutics, Inc.
Jun 08, 2026, 08:00 ET Vasa Therapeutics to Deliver Two Presentations on VS-041 at ECM2026, Featuring Preclinical and First-in-Human Data and Ongoing Phase 1c Trial Design in HFpEF
("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, announced today that Noreen R. Henig, MD, Chief Medical Officer, will deliver two presentations on VS-041 at ECM2026, the Extracellular Matrix Pharmacology Conference, to be held June 14-17,
More news about: Vasa Therapeutics
Jun 08, 2026, 08:00 ET Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
Mr. Lind succeeds Company founder Lawrence G. Miller, MD, who is transitioning to Vice Chair of the BoardMr. Lind brings significant prior CEO, commercial, financial and capital markets experience, including leading Longboard Pharmaceuticals to an acquisition by H. Lundbeck
More news about: Apnimed, Inc.
Jun 08, 2026, 07:00 ET Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
biotechnology company focused on developing small-molecule drugs that target protein misfolding diseases, today announced the appointment of Jae B. Kim, MD, as its Chief Medical Officer (CMO). Dr. Kim joins Protego after serving as Chief Medical Officer of Septerna since 2024.
More news about: Protego Biopharma
Jun 08, 2026, 06:30 ET QUANTUM SPACE, A LEADING SPACE DEFENSE AND ORBITAL MOBILITY COMPANY, TO GO PUBLIC VIA MERGER WITH INFLECTION POINT ACQUISITION CORP. VI
https://app.webinar.net/R0rM30p36JdROCKVILLE, Md., June 8, 2026 /PRNewswire/ -- Quantum Space, LLC (the "Company" or "Quantum Space"), a company building the next
More news about: Quantum Space
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
biological target engagement, and mechanistic biomarker effects. The trial has been funded by Cure Parkinson's.Professor Charalampos Tzoulis, MD, Ph.D, Chief Investigator of the SLEIPNIR Platform and Director of the Neuro-SysMed Center of Excellence for Clinical Neurological Research and the Innovation
More news about: Foresee Pharmaceuticals Co., Ltd.
Jun 08, 2026, 04:30 ET 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry
More news about: Innovent Biologics
Jun 07, 2026, 17:30 ET Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
Lancet."Treating type 2 diabetes early with a combined approach offers a unique opportunity to change the course of the disease," said Vanita R. Aroda, MD, lead author of the study. "Rather than focusing on glucose control alone, this strategy addresses weight, cardiovascular risk, and metabolic health together,
More news about: American Diabetes Association
Jun 07, 2026, 17:30 ET Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
bodyweight.4-6"The therapeutic potential of amylin in type 2 diabetes has been recognized by the medical community for many years," said John B. Buse, MD, PhD, Distinguished Professor of Medicine, Director of the UNC Diabetes Care Center. "Now, in the REIMAGINE trials, we're taking that knowledge forward
More news about: NOVO NORDISK INC.
Jun 07, 2026, 16:45 ET Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
diabetes, one of the most immediate concerns is acute pancreatitis, which can lead to serious short- and long-term complications," said Yu Mi Kang, MD, PhD, MPH, a lead author of the study. "The presented findings suggest that olezarsen lowers the triglyceride levels and reduces the risk of pancreatitis
More news about: American Diabetes Association
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
https://doi.org/10.1001/jama.2026.3277Shapiro MD. Circulation. 2022;146(15):1120-1122. Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862.Data on File. Amgen,
More news about: Amgen
Jun 07, 2026, 14:30 ET Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
also drive meaningful improvements in overall metabolic health, and these findings are encouraging for potential new solutions," said Carel le Roux, MD, PhD, lead author of the study. "For patients, improving metabolic health is about more than weight loss alone, it can help reduce the risk of serious
More news about: American Diabetes Association
Jun 06, 2026, 18:13 ET From Bystanders to Heart Savers: MedStar Health CPR Training Event Puts Power to Save Lives in Community's Hands
SILVER SPRING, Md., June 6, 2026 /PRNewswire/ -- MedStar Health marked CPR & AED Awareness Week with its third annual training event held at Montgomery Blair High School. Nearly 100 attendees learned bystander CPR and automated
More news about: MedStar Health
Jun 06, 2026, 14:45 ET 82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring
therapies are seen in primary care settings, continuous glucose monitoring provides an opportunity to close a visible care gap," said Thomas W. Martens, MD, co-author of the study. "As the first major randomized controlled trial evaluating CGM in individuals with type 2 diabetes not using insulin, these findings
More news about: American Diabetes Association
Jun 06, 2026, 14:30 ET Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
the lives of newly diagnosed individuals with type 2 diabetes through life-changing weight and blood glucose management," said Harpreet Singh Bajaj, MD, MPH, lead author of the study. "The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how
More news about: American Diabetes Association
Jun 06, 2026, 13:00 ET Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions
chronic disease that can cause many complications in the body, contributing to serious comorbidities and broader health issues," said Domenica Rubino, MD, founder and director, Washington Center for Weight Management & Research. "These analyses, across the spectrum of clinical trial programs conducted
More news about: NOVO NORDISK INC.
Jun 06, 2026, 09:07 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
dose escalation of current therapy may get patients to their treatment goals compared to transitioning to a different therapy," said Michael Radin, MD, Executive Medical Director at Novo Nordisk Inc. "These real-world findings directly support the established ADA guidelines, which recommend that many
More news about: Novo Nordisk
Jun 06, 2026, 09:01 ET People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data
dose escalation of current therapy may get patients to their treatment goals compared to transitioning to a different therapy," said Michael Radin, MD, Executive Medical Director at Novo Nordisk Inc. "These real-world findings directly support the established ADA guidelines, which recommend that many
More news about: Novo Nordisk
Jun 06, 2026, 09:00 ET Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
or obesity, especially because a once-monthly dosing could offer a more manageable alternative to today's more frequent injections," said John Buse, MD, PhD, lead author of the study. "For patients, this less frequent dosing may help ease the burden of ongoing treatment and support better long-term adherence
More news about: American Diabetes Association
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
pharmaceuticals."The obesity market is urgently looking for the 'next generation' of therapeutics that go beyond simply suppressing appetite," said Long-Cheng Li, MD, Founder and Chief Executive Officer of Ractigen Therapeutics. "saRNA opens an entirely new frontier in obesity control. By activating the body's own
More news about: Ractigen Therapeutics
Jun 05, 2026, 18:30 ET First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes—Phase 1 and 2 Results"Klara Klein, MD, PhD, and Jeremy Pettus, MDPhase 2 Study: Trial Design, Baseline Characteristics, and Key Glycemic EndpointsPhase 2 Study: Key Secondary Endpoints,
More news about: American Diabetes Association
Jun 05, 2026, 14:43 ET The Inner Circle acknowledges Aashish Valvani, MD acknowledged as a Pinnacle Lifetime Member
2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Aashish Valvani, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to Pulmonology and Critical Care. Aashish Valvani, MD, has established a respected career in medicine, recognized for his expertise in pulmonology
More news about: The Inner Circle
Jun 05, 2026, 12:39 ET St. Joseph's Children's Hospital Cancer Survivor Advocates for Children's Health Care on Capitol Hill
Emergency/Trauma Center for Children, staffed by the region's largest team of board-certified pediatric emergency physicians; and The Daniel J. Plasencia, MD, Children's Chronic Complex Clinic, a national model for legislation supporting similar programs across the country. St. Joseph's Children's Hospital
More news about: St. Joseph's Children's Hospital
Jun 05, 2026, 09:00 ET Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
dataset provides important insights into the clinical outcomes and immune responses observed with DOC1021 in glioblastoma," said Dr. Jay-Jiguang Zhu, MD, PhD, Study Investigator at UTHealth Houston (Department of Neurosurgery). "The findings, including the 12-month survival outcomes observed in a predominantly
More news about: Diakonos Oncology